<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850339</url>
  </required_header>
  <id_info>
    <org_study_id>ANN-001</org_study_id>
    <nct_id>NCT04850339</nct_id>
  </id_info>
  <brief_title>First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ANXV Administered as an Intravenous Infusion to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexin Pharmaceuticals AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexin Pharmaceuticals AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an adaptive, randomised, double-blind, single-centre, placebo-controlled phase I,&#xD;
      First in Human study designed to evaluate the safety, tolerability and pharmacokinetics of&#xD;
      single and multiple intravenous dosing of ANXV in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This First in Human study is divided in two parts. Part I, Single Ascending Dose (SAD), will&#xD;
      explore safety, tolerability and PK of single intravenous doses of ANXV. Part II, Multiple&#xD;
      Ascending Dose (MAD), will explore safety, tolerability and PK of multiple doses (five&#xD;
      consecutive daily doses) of intravenous ANXV.&#xD;
&#xD;
      The objectives of this study are:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      - To evaluate the safety and tolerability of single/multiple ascending doses of ANXV in&#xD;
      healthy male subjects.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      - To determine the PK profile of single/multiple ascending doses of ANXV in healthy male&#xD;
      subjects.&#xD;
&#xD;
      Exploratory objectives:&#xD;
&#xD;
      - To evaluate ADA to ANXV and other relevant parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events.</measure>
    <time_frame>From day 1 (inclusion) until day 35</time_frame>
    <description>Frequency of adverse events at single and multiple ascending doses of ANXV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seriousness of adverse events.</measure>
    <time_frame>From day 1 (inclusion) until day 35</time_frame>
    <description>Seriousness of adverse events at single and multiple ascending doses of ANXV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of adverse events.</measure>
    <time_frame>From day 1 (inclusion) until day 35</time_frame>
    <description>Intensity of adverse events at single and multiple ascending doses of ANXV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: AUClast</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>AUC from time zero to time of last quantifiable analyte concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: Cmax</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>Observed maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: Tmax</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>Time to Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: λz</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>Terminal slope of a semi-logarithmic concentration-time curve (λz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: T½</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>Terminal half life (T½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: CL</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>Clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: Vz</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>Volume of distribution (Vz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of single and multiple ascending doses of ANXV: Fraction excreted in urine (fe)</measure>
    <time_frame>0-24hours after IMP administration</time_frame>
    <description>Fraction excreted in urine (fe)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ANXV single dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ANXV in a single ascending dose pattern in four dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in a single ascending dose pattern in four dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANXV multiple dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ANXV in a multiple ascending dose pattern in three dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in a multiple ascending dose pattern in four dose levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ANXV</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>ANXV multiple dose</arm_group_label>
    <arm_group_label>ANXV single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo multiple dose</arm_group_label>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to give written informed consent for participation in the study.&#xD;
&#xD;
          2. Healthy male subject aged 18-50 years inclusive at screening.&#xD;
&#xD;
          3. BMI ≥ 18.0 and ≤ 30.0 kg/m2 and weight at least 50 kg and no more than 100 kg at&#xD;
             screening.&#xD;
&#xD;
          4. Overtly healthy based on medical history, physical findings, vital signs, ECG and&#xD;
             laboratory values at the time of screening, as judged by the Investigator.&#xD;
&#xD;
          5. Male subjects must be willing to use condom or be vasectomised or practice sexual&#xD;
             abstinence to prevent pregnancy and drug exposure of a partner, and refrain from&#xD;
             donating sperm from the date of dosing until 3 months after (last) dosing with the&#xD;
             IMP. Their female partner of child-bearing potential are expected to use contraceptive&#xD;
             methods with a failure rate of &lt; 1% to prevent pregnancy (combined [oestrogen and&#xD;
             progestogen containing] hormonal contraception associated with inhibition of ovulation&#xD;
             [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated&#xD;
             with inhibition of ovulation [oral, injectable, implantable], intrauterine device&#xD;
             [IUD] or intrauterine hormone-releasing system [IUS]).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             Investigator, may either put the subject at risk because of participation in the&#xD;
             study, or influence the results or the subject's ability to participate in the study.&#xD;
&#xD;
          2. Any clinically significant illness, medical/surgical procedure or trauma within 4&#xD;
             weeks of the first administration of IMP.&#xD;
&#xD;
          3. Malignancy within the past 5 years with the exception of in situ removal of basal cell&#xD;
             carcinoma.&#xD;
&#xD;
          4. Any planned major surgery within the duration of the study.&#xD;
&#xD;
          5. Any positive result on screening for serum hepatitis B surface antigen (HbsAg),&#xD;
             hepatitis C antibody and Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          6. History of thromboembolic events.&#xD;
&#xD;
          7. History of significant bleeding (gross haematuria, haemoptysis, gastrointestinal tract&#xD;
             bleeding).&#xD;
&#xD;
          8. Evidence or history of a hypercoagulable state (e.g. shortened APTT).&#xD;
&#xD;
          9. Prior exposure to recombinant Annexin A5 (for diagnostic purposes).&#xD;
&#xD;
         10. Any history of coronary artery disease or cerebrovascular accident.&#xD;
&#xD;
         11. Known cardiac disease, cardiac anomaly or cardiac deformity.&#xD;
&#xD;
         12. Known heredity for autoimmune disease with described presence of potentially&#xD;
             pathogenic Annexin A5 antibodies, e.g. antiphospholipid syndrome, systemic lupus&#xD;
             erythematosus or systemic sclerosis, as judged by the Investigator.&#xD;
&#xD;
         13. Any history of or active peptic ulcer disease.&#xD;
&#xD;
         14. Any clinically significant disease affecting the respiratory tract (e.g. obstructive&#xD;
             and restrictive respiratory disease, chronic respiratory disease such as alveolitis,&#xD;
             inflammatory respiratory disease, autoimmune respiratory disease, present respiratory&#xD;
             infections, pulmonary vascular disease) that would influence the results of the study&#xD;
             or the subject's ability to participate in the study, as judged by the Investigator.&#xD;
&#xD;
         15. eGFR (based on plasma-creatinine) outside of normal range at screening or known renal&#xD;
             impairment (≤70 mL/min).&#xD;
&#xD;
         16. Vaccination with live-attenuated vaccines within 4 weeks of the screening visit.&#xD;
&#xD;
         17. After 5 minutes supine rest at the time of screening, any vital signs values outside&#xD;
             the following ranges:&#xD;
&#xD;
               -  Systolic blood pressure &lt;90 or &gt;140 mmHg, or&#xD;
&#xD;
               -  Diastolic blood pressure &lt;40 or &gt;90 mmHg, or&#xD;
&#xD;
               -  Pulse &lt;40 or &gt;100 bpm&#xD;
&#xD;
         18. Current evidence or history of bacterial, viral or fungal infections within 7 days&#xD;
             before (first) IMP administration as judged by the Investigator.&#xD;
&#xD;
         19. Prolonged QTcF (&gt;450 ms), cardiac arrhythmias or any clinically significant&#xD;
             abnormalities in the resting ECG at the time of screening, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         20. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as&#xD;
             judged by the Investigator, or history of hypersensitivity to drugs with a similar&#xD;
             chemical structure or class to ANXV.&#xD;
&#xD;
         21. Regular use of any prescribed or non-prescribed medication including antacids,&#xD;
             analgesics, herbal remedies, vitamins and minerals within two weeks prior to the&#xD;
             (first) administration of IMP, except occasional intake of paracetamol (maximum 2,000&#xD;
             mg/day; and not exceeding 3,000 mg/week), at the discretion of the Investigator and&#xD;
             nasal decongestants without cortisone, antihistamine or anticholinergics for a maximum&#xD;
             of 10 days, at the discretion of the Investigator.&#xD;
&#xD;
         22. Planned treatment or treatment with another investigational drug within 3 months prior&#xD;
             to Day -1. Subjects consented and screened but not dosed in previous phase I studies&#xD;
             are not excluded.&#xD;
&#xD;
         23. Current smokers or users of nicotine products. Smokers that stopped smoking &lt;3 months&#xD;
             prior to screening.&#xD;
&#xD;
         24. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit&#xD;
             prior to administration of the IMP.&#xD;
&#xD;
         25. History of alcohol abuse or excessive intake of alcohol, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         26. Presence or history of drug abuse, as judged by the Investigator.&#xD;
&#xD;
         27. History of, or current use of, anabolic steroids.&#xD;
&#xD;
         28. Excessive caffeine consumption defined by a daily intake of &gt;5 cups of caffeine&#xD;
             containing beverages.&#xD;
&#xD;
         29. Intake of xanthine and/or taurine containing energy drinks within 2 days prior to&#xD;
             screening.&#xD;
&#xD;
         30. Plasma donation within one month of screening or blood donation (or corresponding&#xD;
             blood loss) of &gt;450 ml during the three months prior to screening.&#xD;
&#xD;
         31. Investigator considers the subject unlikely to comply with study procedures,&#xD;
             restrictions and requirements, or unfit for participation for any other reason.&#xD;
&#xD;
         32. Previous confirmed COVID-19 disease requiring hospital care or positive COVID-19 test&#xD;
             on admission to the clinic.&#xD;
&#xD;
         33. Insufficient venous access for study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Frostegård, MD</last_name>
    <role>Study Director</role>
    <affiliation>Annexin Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Frostegård</last_name>
    <phone>+46701104258</phone>
    <email>anna.frostegard@annexinpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Suchdev</last_name>
    <phone>+46702079788</phone>
    <email>susan.suchdev@annexinpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marieke Geel</last_name>
      <phone>+31503048000</phone>
      <email>Marieke.Geel@qps.com</email>
    </contact>
    <investigator>
      <last_name>Christine Voors</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

